Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 5/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5624374 | 0.84 | F10 (0.46) | MAPK1GAAF10MEN1KMT2A | |
| SCHEMBL5437504 | 0.80 | RHOC (0.52) | ALDH1A1MAPK1GAAF10MEN1 | |
| SCHEMBL6460450 | 0.74 | ITGB3 (0.47) | ALDH1A1MAPK1NAMPTGAAF10 | |
| SCHEMBL6460444 | 0.71 | F10 (0.48) | LMNAMAPK1F10 | |
| SCHEMBL1379531 | 0.71 | F10 (0.52) | ALDH1A1LMNAMAPK1GAAF10 | |
| SCHEMBL5628377 | 0.69 | NAMPT (0.56) | ALDH1A1HDAC3ROCK2LMNANAMPT | |
| SCHEMBL5540070 | 0.69 | NAMPT (0.73) | ALDH1A1HDAC3LMNANAMPTGRM5 | |
| SCHEMBL23518805 | 0.68 | NAMPT (0.55) | ALDH1A1HDAC3ROCK2NAMPTGRM5 | |
| SCHEMBL5433503 | 0.68 | CYP1A2 (0.49) | F10MEN1KMT2A | |
| SCHEMBL1378839 | 0.67 | F10 (0.45) | HDAC3LMNAMAPK1GAAF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | ALDH1A1 2861/4885HDAC3 3029/4885ROCK2 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.